Company Description
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China.
The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang.
It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors.
China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
| Country | China |
| Founded | 2005 |
| IPO Date | Jan 4, 2019 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 56 |
| CEO | Feng Zhou |
Contact Details
Address: 178 Taidong Road North Taizhou, 225300 China | |
| Phone | 86 523 8629 8290 |
| Website | sxtchina.com |
Stock Details
| Ticker Symbol | SXTC |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001723980 |
| CUSIP Number | G2161P165 |
| ISIN Number | VGG2161P1650 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Feng Zhou | Chairman of the Board and Co-Chief Executive Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 7, 2026 | F-3 | Filing |
| Jul 6, 2026 | 6-K | Report of foreign issuer |
| Jul 1, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Jun 1, 2026 | 6-K | Report of foreign issuer |
| Jun 1, 2026 | 424B5 | Filing |
| May 4, 2026 | 6-K | Report of foreign issuer |
| Apr 9, 2026 | 424B5 | Filing |
| Apr 9, 2026 | 6-K | Report of foreign issuer |
| Jan 13, 2026 | 6-K | Report of foreign issuer |
| Jan 12, 2026 | 424B5 | Filing |